ATE287413T1 - Verfahren zur herstellung des lna phosphoramidite - Google Patents

Verfahren zur herstellung des lna phosphoramidite

Info

Publication number
ATE287413T1
ATE287413T1 AT02764561T AT02764561T ATE287413T1 AT E287413 T1 ATE287413 T1 AT E287413T1 AT 02764561 T AT02764561 T AT 02764561T AT 02764561 T AT02764561 T AT 02764561T AT E287413 T1 ATE287413 T1 AT E287413T1
Authority
AT
Austria
Prior art keywords
producing
cyanoethyl
phosphoramidite
lna
lna phosphoramidite
Prior art date
Application number
AT02764561T
Other languages
English (en)
Inventor
Troels Koch
Christoph Rosenbohm
Daniel Sejer Pedersen
Original Assignee
Santaris Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santaris Pharma As filed Critical Santaris Pharma As
Application granted granted Critical
Publication of ATE287413T1 publication Critical patent/ATE287413T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Luminescent Compositions (AREA)
  • Saccharide Compounds (AREA)
AT02764561T 2001-07-12 2002-07-12 Verfahren zur herstellung des lna phosphoramidite ATE287413T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200101095 2001-07-12
PCT/DK2002/000488 WO2003006475A2 (en) 2001-07-12 2002-07-12 Method for preparation of lna phosphoramidites

Publications (1)

Publication Number Publication Date
ATE287413T1 true ATE287413T1 (de) 2005-02-15

Family

ID=8160624

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02764561T ATE287413T1 (de) 2001-07-12 2002-07-12 Verfahren zur herstellung des lna phosphoramidite

Country Status (7)

Country Link
EP (1) EP1409497B1 (de)
JP (1) JP4402454B2 (de)
AT (1) ATE287413T1 (de)
AU (1) AU2002328792A1 (de)
DE (1) DE60202681T2 (de)
DK (1) DK1409497T3 (de)
WO (1) WO2003006475A2 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2264172T1 (sl) 2002-04-05 2017-12-29 Roche Innovation Center Copenhagen A/S Oligomerne spojine za modulacijo izražanja HIF-1alfa
US7713738B2 (en) 2003-02-10 2010-05-11 Enzon Pharmaceuticals, Inc. Oligomeric compounds for the modulation of survivin expression
MXPA05008319A (es) 2003-02-10 2006-02-28 Santaris Pharma As Compuestos oligomericos para la modulacion de la expresion de survivina.
DK1606406T4 (da) 2003-03-21 2013-12-16 Santaris Pharma As Short Interfering RNA (siRNA) Analogues
AU2004303464B2 (en) 2003-12-23 2009-10-01 Santaris Pharma A/S Oligomeric compounds for the modulation of BCL-2
US9447138B2 (en) 2004-11-09 2016-09-20 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
WO2006050732A2 (en) 2004-11-09 2006-05-18 Santaris Pharma A/S Lna oligonucleotides and the treatment of cancer
AU2005304112B2 (en) 2004-11-09 2009-06-04 Roche Innovation Center Copenhagen A/S Potent LNA oligonucleotides for the inhibition of HIF-1a expression
EP3000480A1 (de) 2005-12-01 2016-03-30 ProNAi Therapeutics, Inc. Krebstherapien und dabei verwendete pharmazeutische zusammensetzungen
ES2556128T3 (es) 2006-03-23 2016-01-13 Roche Innovation Center Copenhagen A/S ARN interfiriente pequeño internamente segmentado
NZ571569A (en) 2006-04-03 2011-09-30 Santaris Pharma As Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides
CA2649045C (en) 2006-04-03 2019-06-11 Santaris Pharma A/S Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
WO2008113830A1 (en) 2007-03-22 2008-09-25 Santaris Pharma A/S Rna antagonist compounds for the inhibition of apo-b100 expression
DK2149605T3 (da) 2007-03-22 2013-09-30 Santaris Pharma As Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
WO2008153933A2 (en) 2007-06-06 2008-12-18 Avi Biopharma, Inc. Soluble her2 and her3 splice variant proteins, splice-switching oligonucleotides, and their use in the treatment of disease
WO2009027978A1 (en) 2007-08-30 2009-03-05 Hadasit Medical Research Services & Development Ltd. NUCLEIC ACID SEQUENCES COMPRISING NF-ϰB BINDING SITE WITHIN O(6)-METHYLGUANINE-DNA-METHYLTRANSFERASE (MGMT) PROMOTER REGION AND USES THEREOF FOR THE TREATMENT OF CANCER AND IMMUNE-RELATED DISORDERS
WO2009043353A2 (en) 2007-10-04 2009-04-09 Santaris Pharma A/S Micromirs
EP2212437A4 (de) 2007-11-07 2011-09-28 Univ British Columbia Mikrofluidische vorrichtung und verfahren zu ihrer anwendung
US8404659B2 (en) 2008-03-07 2013-03-26 Santaris Pharma A/S Pharmaceutical compositions for treatment of MicroRNA related diseases
EP2315832B1 (de) 2008-08-01 2015-04-08 Roche Innovation Center Copenhagen A/S Micro-rna-vermittelte modulation koloniestimulierender faktoren
ES2599979T3 (es) 2009-04-24 2017-02-06 Roche Innovation Center Copenhagen A/S Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón
WO2011009697A1 (en) 2009-07-21 2011-01-27 Santaris Pharma A/S Antisense oligomers targeting pcsk9
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
GB201012418D0 (en) 2010-07-23 2010-09-08 Santaris Pharma As Process
EP3372684B1 (de) 2010-08-24 2020-10-07 Sirna Therapeutics, Inc. Einsträngige rnai-mittel mit einem internen nukleinsäurefreien spacer
KR20150087270A (ko) 2012-11-05 2015-07-29 프로나이 테라퓨틱스, 인코포레이티드 Bcl2 발현 조절에 의한 암치료용 바이오마커 이용 방법
EP2943570B1 (de) 2013-01-14 2018-01-03 Pierfrancesco Tassone Inhibitoren von mirnas 221 und 222 zur antitumorwirkung bei multiplem myelom
EP3591054A1 (de) 2013-06-27 2020-01-08 Roche Innovation Center Copenhagen A/S Gegen pcsk9 gerichtete antisense-oligomere und konjugate
WO2015075166A1 (en) 2013-11-22 2015-05-28 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of a bacterial infection
EP3099798B1 (de) 2014-01-29 2018-06-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Oligonukleotide und methoden zur inhibierung oder verminderung von bakteriellen biofilmen
GB201410693D0 (en) 2014-06-16 2014-07-30 Univ Southampton Splicing modulation
WO2016041058A1 (en) 2014-09-18 2016-03-24 The University Of British Columbia Allele-specific therapy for huntington disease haplotypes
JP6867945B2 (ja) 2014-10-03 2021-05-12 コールド スプリング ハーバー ラボラトリー 核内遺伝子出力の標的とされた増強
DK3341479T3 (da) 2015-08-24 2020-02-24 Roche Innovation Ct Copenhagen As LNA-G-Proces
WO2017060731A1 (en) 2015-10-09 2017-04-13 University Of Southampton Modulation of gene expression and screening for deregulated protein expression
US11096956B2 (en) 2015-12-14 2021-08-24 Stoke Therapeutics, Inc. Antisense oligomers and uses thereof
SG11201804443UA (en) 2015-12-14 2018-06-28 Cold Spring Harbor Laboratory Antisense oligomers for treatment of autosomal dominant mental retardation-5 and dravet syndrome
WO2018024849A1 (en) 2016-08-03 2018-02-08 Aalborg Universitet ANTISENSE OLIGONUCLEOTIDES (ASOs) DESIGNED TO INHIBIT IMMUNE CHECKPOINT PROTEINS
LT3673080T (lt) 2017-08-25 2023-12-27 Stoke Therapeutics, Inc. Priešprasminiai oligomerai, skirti būklėms ir ligoms gydyti
US11261445B2 (en) 2017-10-17 2022-03-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Combination treatment for cystic fibrosis
US20220251567A1 (en) 2019-07-10 2022-08-11 Inserm (Institut National De La Santè Et De La Recherche Médicale) Methods for the treatment of epilepsy
IT201900017234A1 (it) 2019-09-25 2021-03-25 Int Centre For Genetic Engineering And Biotechnology Anti-miRNA per il trattamento del leiomioma
WO2021074657A1 (en) 2019-10-17 2021-04-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Combination treatment for cystic fibrosis
IL292286A (en) * 2019-10-18 2022-06-01 Daiichi Sankyo Co Ltd Production method for bicyclic phosphoramidite
EP4059944A4 (de) * 2019-11-13 2024-04-10 Nippon Shinyaku Co., Ltd. Verfahren zur herstellung einer oligonukleidsäureverbindung
US20230016983A1 (en) 2019-11-19 2023-01-19 lNSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) Antisense oligonucleotides and thier use for the treatment of cancer
MX2022014151A (es) 2020-05-11 2022-11-30 Stoke Therapeutics Inc Oligomeros antisentido de opa1 para tratamiento de afecciones y enfermedades.
IL299771A (en) 2020-07-10 2023-03-01 Inst Nat Sante Rech Med Methods and compounds for the treatment of epilepsy
JPWO2022124410A1 (de) * 2020-12-11 2022-06-16
IL304956A (en) 2021-02-12 2023-10-01 Merand Pharmaceuticals Inc Materials, compositions and methods for treating hypoxia and ischemia-related disorders
BR112023019582A2 (pt) 2021-03-26 2023-12-05 Neumirna Therapeutics Aps Oligonucleotídeo antissenso inibidor de microrna-27b
EP4313073A1 (de) 2021-03-26 2024-02-07 Neumirna Therapeutics ApS Mikrorna-134-inhibitoren
EP4347824A1 (de) 2021-06-04 2024-04-10 Neumirna Therapeutics ApS Antisense oligonukleotide gegen adenosinkinase
AU2022329834A1 (en) 2021-08-17 2024-03-07 Korea Advanced Institute Of Science And Technology Antisense oligonucleotide targeting cav3.1 gene and uses thereof
EP4388096A1 (de) 2021-08-19 2024-06-26 Neumirna Therapeutics ApS Antisense oligonukleotide gegen adenosinkinase
WO2023152369A1 (en) 2022-02-14 2023-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
WO2024017990A1 (en) 2022-07-21 2024-01-25 Institut National de la Santé et de la Recherche Médicale Methods and compositions for treating chronic pain disorders
EP4332239A1 (de) 2022-08-30 2024-03-06 Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" - IRST S.r.l. Mir-basierter test zur diagnose und prognose von gastro-entero-pankreatischen neuroendokrinen tumoren
WO2024146935A1 (en) 2023-01-06 2024-07-11 Institut National de la Santé et de la Recherche Médicale Intravenous administration of antisense oligonucleotides for the treatment of pain

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016540A1 (en) * 1996-10-15 1998-04-23 Proligo Llc Improved coupling activators for oligonucleotide synthesis

Also Published As

Publication number Publication date
WO2003006475A2 (en) 2003-01-23
JP2004536125A (ja) 2004-12-02
DK1409497T3 (da) 2005-05-30
JP4402454B2 (ja) 2010-01-20
DE60202681T2 (de) 2006-01-12
EP1409497B1 (de) 2005-01-19
WO2003006475A3 (en) 2004-02-26
DE60202681D1 (de) 2005-02-24
EP1409497A2 (de) 2004-04-21
AU2002328792A1 (en) 2003-01-29

Similar Documents

Publication Publication Date Title
ATE287413T1 (de) Verfahren zur herstellung des lna phosphoramidite
ATE506372T1 (de) Verfahren zur herstellung von nukleosidderivate
ATE328476T1 (de) Verfahren zur verbesserung der reproduktionsleistung bei geflügel
YU27304A (sh) Novi dihidropteridinoni, postupak za njihovo dobijanje i njihova primena kao lekova
ATE410412T1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
DE60134581D1 (de) Verfahren zur Herstellung von Siliziumkarbideinkristall
ATE372343T1 (de) Verfahren zur herstellung von 6-alkoxy-(6h)- dibenz(c,e)(1,2)-oxaphosphorinen
ATE266030T1 (de) 1,4,7,10-tetraazabicyclo(8.2.2)tetradecan-2-on, verfahren zu ihrer herstellung und ihrer verwendung für die herstellung von tetraazamacrocyclen
ATE266037T1 (de) Verfahren zur herstellung von phoshphorothioate triestere
DE60138443D1 (de) Verfahren zur herstellung von siliziumeinkristallen
DE60124289D1 (de) Verfahren zur herstellung von 21-hydroxy-6,19-oxidoprogesteron (21oh-6op)
DE60228724D1 (de) Verfahren zur herstellung von beraprost und dessen salzen
DE69824839D1 (de) Verfahren zur herstellung von 2-aryl-3-aryl-5-halogen-pyridinen, verwendbar als cox-2 inhibitoren
DE50200809D1 (de) Verfahren zur herstellung von n-phosphonomethyliminodiessigsäure
ATE278702T1 (de) Verfahren zur synthese von phosphorothioat- oligonukelotiden
DE60308066D1 (de) Verfahren zur herstellung von hyperpolarisiertem 129xe
DE60142201D1 (de) Verfahren zur Herstellung von einkristallinem Siliziumkarbid
DE69808771D1 (de) Ein verfahren zur herstellung von tetraaza makrocyclen
ATE466836T1 (de) Verfahren zur herstellung von alpha- difluormethylornithin (dfmo)
ATE267799T1 (de) Ein verfahren zur herstellung von (2s,2'r,3'r)-2- (2,3-dicarboxycyclopropyl)-glycin
ATE302749T1 (de) Verfahren zur herstellung von 5-aminosalicylsäure
ATE332905T1 (de) Verfahren zur herstellung von acylphosphinoxiden
DE60118262D1 (de) Verfahren zur Herstellung von bis-(4-Amino-1-pyridinium)-Alkanen
DE50003759D1 (de) Verfahren zur herstellung von n-(4,5-bis-methansulfonyl-2-methyl-benzoyl)-guanidin, hydrochlorid
ATE250042T1 (de) Verfahren zur herstellung von cyclen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties